The role of anti-IgE (omalizumab) in the management of severe recalcitrant paediatric atopic eczema
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Omalizumab (Primary)
- Indications Eczema
- Focus Therapeutic Use
- Acronyms ADAPT
- 02 Jul 2016 Status changed from active, no longer recruiting to completed.
- 01 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ISRCTN: Current Controlled Trials.
- 02 Dec 2015 Accrual to date is 59% according to United Kingdom Clinical Research Network